|
Feb 17
|
Novo Nordisk A/S (NVO): Among the Best Drug Stocks to Buy Now
|
|
Feb 16
|
2 Important Insights From Novo Nordisk's Earnings Call
|
|
Feb 14
|
Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl ad
|
|
Feb 14
|
Moderna's Q4 loss: Can the pharma giant get to profitability?
|
|
Feb 14
|
Novo Shares Hit as Super Bowl Weight-Loss Ad Shows Copycat Risk
|
|
Feb 14
|
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
|
|
Feb 14
|
Is Novo Nordisk A/S (NVO) the Best Foreign Dividend Stock to Buy According to Analysts?
|
|
Feb 13
|
Hims & Hers stock sees another spike in trading days after Super Bowl ad
|
|
Feb 13
|
Why Novo Nordisk Stock Keeps Going Down
|
|
Feb 12
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Feb 12
|
Novo Nordisk initiated by Morgan Stanley on equal weight coverage
|
|
Feb 12
|
Why the 'best hedge' against the AI rally losing steam in 2025 is healthcare: Morning Brief
|
|
Feb 12
|
Novo Nordisk A/S (NVO): Among the Best International Dividend Stocks to Buy Now
|
|
Feb 11
|
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
|
|
Feb 10
|
Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business
|
|
Jan 4
|
Better Buy: Novo Nordisk vs. AstraZeneca
|
|
Jan 3
|
From Davids to Goliaths: the GLP-1RA gold rush
|
|
Jan 2
|
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
|
|
Jan 2
|
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
|
|
Jan 2
|
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
|